Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If the $11m were that much of an issue they would go through Nasdaq appeal process. Instead they voluntarily choosed to get listed on OTC, they will raise cash with no problem especially after the confirmed reversal on stock price from a technical point of view.
It is only for a few months, after success they will go back to Nasdaq.
Yeah but then no cash raises at ridiculous prices and less outstanding shares.
It is only beneficial if the add to position was meaningful.
If only Linda Powers had stated enrollment number and confirm primary endpoint schedule publicly before it would probably never have been a penny stock.
Their technology didn't cover large indications unlike DCVax platform, the takeover was only at 1.5 billions in NWBO case we can expect a buyout at 10 billions.
Can't be ruled out...unfortunately. If we look at history of Nadasq directors there are some really nefarious names.
I doubt technical analysis matter anymore, it looks good but imminent trial update will do the job imo.
Just for your information Woodford buy stocks that are not even quoted, therefore I don't think that OTC market is a problem...
I told you folks
It can only be withdrawn from Nasdaq once you know. First hour of the session was your chance to buy near lowest of what looks like a double bottom on the chart now.
Buying opportunity today as some market participants will have to sell because they can't hold an OTC stock. Probably last possibility to buy near support before trial results.
Because management didn't tell me that, if aliases on this board have private information I'd like to see a proof before believing it.
I care but he didn't say that.
The problem is that you always claimed that we had interim analysis performed but management didn't warn us.
Yet you believe that this time management will warn us when primary endpoint analysis will start.
The "I talked to Les" don't work for me especially on this message board. If Adam Feuerstein was certain we won't have results in November he would post under his real name, yet I only see the "I talked to Les" from aliases.
The truth is that Les never gave accurate date for results, the only accurate date is on clinicaltrials.gov and it is November. I think analysis started in September and they think they can publish in November.
The difference in PFS is just terrific, methylation of the MGMT promoter is even a better prognosis factor than extent of resection. And we know that MGMT promoter methylation is more common in the proneural than in the mesenchymal type while DCVax-L had the most impressive results in the mesenchymal type.
Seriously...GL to shorts !
Lol because some fat finger dumped 150k shares near support at close with most of market already offline you think it change financing terms ?
Just FYI 43.5 is bigger than 38.
Anyway at this stage it doesn't matter, we're way too close to finish line and at current outstanding shares (with latest financing included) the billion mark is at more than 15x current price. FYI CPXX was bought at 1.5 billion earlier this year.
Perhaps you forgot a very small detail...finish line is here for DCVax-L. Even if Nasdaq rule was $10 minimum instead of $1 the company can still reach compliance without R/S.
You have to be total crazy to short at this price. Now that Trump won and that financing is behind us he has to pray we don't get results this month otherwise he is dead.
Great news for biotechnology. With Clinton surprisingly out expect large surperformance in sector for coming months/years.
The month of completion on clinicaltrials.gov usually coincide with results unless it is updated.
As long as this date is not updated there is significant "risk" that trial results get published overnight.
They will have more like 3 secs at best...provided manipulation is still working. There has been so many BS reports and posts about this stock that I doubt beating the horse work anymore.
Avastin is associated with increased adverse events, not DCVax-L. If Avastin was just as safe it would have received approval as first line therapy.
Ok I now understand why so many people on message boards were nervous lately hoping for a crash. But I disagree Maverick these shares were shorted under 50 cents, that is why they are very nervous at the moment as cash raise is behind us.
With primary endpoint looming that will be a horrible November for them for sure especially if they added to position.
For the long side, an increase in short interest is good news as it means potential for bidding.
It is too bad we don't have survival data stratified by methylation status of MGMT promoter though.
It is very unlikely, mPFS was 26.4 months in phase 1/2. Celldex in its phase 2 trial ACT III had all patients with gross total resection and excluded all rapid progressors yet mPFS was only 12 months from diagnosis.
Even if there were only 20 patients in DCVax-L that is stunning that they manage to perform more than 2x better than placebo (Rintega).
It is time people come back to reality, this improvement is way too huge to not be caused by vaccine.
It will succeed anyway, I don't see how this can possibly fail.
IMUC narrowly failed in phase 2 because there were not enough HLA-A2+ patients while in phase 1 70% of them were HLA-A2+ (subgroup on which ICT-107 is most effective).
DCVax-L phase 1 had a correct number of mesenchymal subtype (30%), on which vaccine seem to work the best so we won't see different OS number (36.4 months). There is no way a placebo reach 36 months mOS or 26 months mPFS.
Even if you don't believe in the science it is not a good move to short so low so close to primary endpoint, and nobody did. Check the published short interest on Nasdaq site, it has not increased in a year.
And on the other side I'm sure plenty of people that don't believe at all in DCVax will buy shares in coming weeks just to benefit from the amazing risk/reward going into binary event.
But with all this good data released I don't see how anyone that did serious DD would not be convinced that this trial will succeed.
Results come soon, they would not update with a date in only a week if not sure about completion. That is certain and obvious just like the trend reversal on share price. Any decent technical analyst can notice there was a shift in price behaviour after Nasdaq accepted Cognate plan in early September.
This speculation brought by AF about what new investor did or will do with his shares is far fetched, it is like saying that Woodford will buy the whole float today. Can anyone be 100% sure that it won't happen ? Hell no but it is not a good reason to expect that this scenario is the one with the greatest odds.
I don't know if that is desperation or nervousness, but that is understandable considering AF gambled his reputation and career on this pick. I suspect he will try to hedge his official position by betting the farm this week so that even if he loses his job and reputation after results he will still retire rich. I think he is overestimating his market impact though, if he had one it has already been priced in for a long time as he is constantly launching attacks on this company.
It is stupid to trust him though, he said the same thing about last cash raises covered with warrants and the price still skyrocketed more than doubling from offering prices at 35 cents.
He told us it would go BK but here we are heading toward trial completion and it was really stupid to believe him anyway.
If he was really a usefull tool he would have warned about about Cognate plan acceptation by Nasdaq, he would have warned us that DCVax Direct updates would be very impressive so we could bet the farm at all time low and I doubt very much we will be able to see these low prices anymore now that we know we are very close to primary endpoint, though 50 cents is still a big bargain.
Technical analysis tells us it is bottoming, I would rather trust that and the impressive clinical data than someone that has not been able to predict all the good news we witnessed in September.
AF told us to short Celator Pharmaceuticals at $1 and we all missed a 2900% move. Thanks AF !
This time he claims something that he thinks would a bad news but it would actually be a very bullish one. If that investor is really a short term player then he is already totally hedged and his sale is priced in.
If he is right then we're definitely going to skyrocket and nobody will be able to stop it especially with trial results coming so close.
If they think it is easy then they don't know they are commiting suicide, anyone that shorted in the last months so close to primary endpoint and with such a low valuation is taking incredible risks. And those risks are the rewards for longs.
People that picked CPXX as a short say they are good at their job. I disagree.
When you are good you can be wrong but at least you learn your lesson. A 60m biotech in late stage p3 powered by strong data in previous trials is a screaming buy not a short target.
Using logic here is the key, if a stock goes from $1 to $30 who is the fool ? The one that risk -50% to -80% or the one that risk -2900% ?
In NWBO case I'm not even sure it can lose 50% in case of very unlikely failure in glioblastoma. DCVax-Direct is a very big component of valuation now and it can be used in many indications.
Primary endpoint in a week for a phIII and market cap is only 60m, so we will get a scenario a la Celator Pharmaceuticals possibly even more spectacular with quadruple digit gains in no time.
These kind of moves are the signs of a clueless market disconnected from industry realities, if participants were really aware of what is going on we wouldn't get moves like this Tobira Therapeutics buyout at a huge premium.
In a perfect world, risk/reward should be 50/50. When stocks move 500% or more in no time it is not sane especially during those times when we don't suffer a financial crisis.
So what went wrong with those stocks ? Poor communication ? Manipulation ? May be a bit of both.
26m shares cancelled (18m virtual + 8m real ) on September 6, let's not forget that.
Your 3.8m increase in Accounts payable, if possible by law, means more shares will be cancelled.
We only have 130m outstanding shares after last offering, it means market cap is around 60m today. That is just completely mad considering we are only 1 week away from primary endpoint. No wonder why price is bottoming, once all the weak hands have been digested we go up for sure.
You already said we should have had an offering early October at latest, it is clear you are way overestimating cash burn, Q3 cash burn was much lower than in Q2, we get confirmation soon with 10-Q.
Cashburn is is a downtrend, I'm doing projections based on hypothesis that it carries on to go down at the same pace.
Primary endpoint is next month as stated on clinical.gov, I don't think it will get delayed this time as last update was quite fresh on October 12.
Investigation report should be released next month at next yonemura's lawsuit meeting.
Capitulation is over, 50 days MA got very well defended today as it didn't even got breached intraday.
It is very unlikely we get another buying opportunity until investigation report and trial results (both scheduled next month) as 5m should last 6 months in best case scenario if they don't start phase 2 trials asap.
Cash burn trend is going so sharply lower that unless they start phase 2 trials asap it is possible those 5 millions last 6 months with that pace.
Back above 50 cents next week Turtle perhaps even on Monday, I'm sorry if you sold everything at all time low.
Friday was the last capitulation before trial results, big volume and large shadow on the candle.